Pretransplant Immune Checkpoint Inhibitor Treatment for Intermediate-advanced Hepatocellular Carcinoma in Living Donor Liver Transplantation [0.03%]
活体肝移植前免疫检查点抑制剂治疗中晚期肝细胞癌
Chih-Hsien Cheng,Hao-Wen Shi,Yin Lai et al.
Chih-Hsien Cheng et al.
Background: The use of immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) is gaining momentum.
Rheumatic Immune-Related Adverse Events: Immune Checkpoint Inhibitor Therapy and Ramifications for Health Disparities [0.03%]
风湿免疫相关不良事件：免疫检查点抑制剂治疗及其对医疗差异的影响
Laura Kobashigawa,Nicole Zagelbaum,Katherine Ruddy et al.
Laura Kobashigawa et al.
Keywords: access to health care; healthcare disparity; immune checkpoint inhibitors (icis); immune-related adverse event (irae); patient referral. Copyright © 2025, Kobashigawa et al.
Zixin Wang,Tengjiao Wang
Zixin Wang
Immunotherapy exerts its antitumor effects primarily by modulating the immunosuppressive tumor microenvironment and includes modalities such as immune checkpoint inhibitors (ICIs), adoptive cell therapies (ACTs), and cancer vaccines. Among these, ICIs and ACT have garnered significant attention.
Postoperative immune checkpoint inhibitors plus anti-angiogenesis for hepatitis B virus-associated hepatocellular carcinoma: Analyzing the evidence and future prospects [0.03%]
术后免疫检查点抑制剂联合抗血管生成治疗乙型肝炎病毒相关性肝细胞癌：证据分析与未来展望
Arunkumar Krishnan,Diptasree Mukherjee
Arunkumar Krishnan
A recent study by Lu et al examined the potential benefits of postoperative combined therapy (PCT) using anti-programmed cell death protein-1/PD-ligand-1 and anti-vascular endothelial growth factor agents for patients with hepatitis B virus...
Immune checkpoint molecules signal regulatory protein alpha in the development of hepatocellular carcinoma [0.03%]
免疫检查点分子信号调节蛋白alpha在肝细胞癌发生发展中的作用研究
Xue Zhang,Dong-Bo Chen,Rui Zhang et al.
Xue Zhang et al.
In recent years, immune checkpoint inhibitors have emerged as a key strategy in cancer treatment. However, anti-programmed cell death 1/programmed death ligand 1 therapies, one of the main immunotherapeutic approaches, only elicit a response in only approximately 20% of advanced HCC.
Rapid cholestasis improvement as key strategy for steroid-refractory immune-related cholangitis: A case report [0.03%]
重症联合免疫缺陷肝炎相关肉芽肿伴胆管炎糖皮质激素抵抗一例及其治疗策略讨论
Zhao Gao,Ji-Xin Zhang,Xiao-Dong Tian et al.
Zhao Gao et al.
Background: Steroid-refractory immune-related cholangitis, characterized by biliary obstruction, can be caused by drugs such as immune checkpoint inhibitors (ICIs).
C-C motif glycoprotein ligand 5 (CCL5) and its GPCR CCR5: Macromolecular game-changers in cancer biology [0.03%]
趋化因子C-C基序配体5(CCL5)及其受体CCR5在癌症生物学中的作用：巨分子领域的游戏规则改变者
Kosar Ghasemi
Kosar Ghasemi
Translational techniques employing CCR5 antagonists such as Maraviroc, GAG-binding modulators, glycoengineered CCL5 variants, delivery systems, and their integration with immune checkpoint inhibitors (ICIs) and targeted therapies are highlighted for their considerable therapeutic promise.
Resectable locally advanced head and neck squamous cell carcinoma: cut first or immune checkpoint inhibitors first? [0.03%]
可切除的局部晚期头颈部鳞状细胞癌：先手术还是先免疫检查点抑制剂？
Zainab A A Al Maqrashi,Adi Kartolo,Brandon M Meyers
Zainab A A Al Maqrashi
SMC4 promotes immune evasion by inhibiting endogenous interferon signaling and upregulating PD-L1 expression in triple negative breast cancer [0.03%]
SMC4通过抑制内源性干扰素信号并上调PD-L1表达促进三阴性乳腺癌的免疫逃逸
Jiayu Zhu,Lei Zhang,Xue Hui et al.
Jiayu Zhu et al.
Enhancing the efficacy of immune checkpoint inhibitors (ICIs) remains a formidable challenge for TNBC. Structural maintenance of chromosome 4 (SMC4), a regulator of genomic stability, has been implicated in tumor progression.
Quality of Life results and survival outcomes in trials of immunotherapy in advanced cancers: a systematic review and meta-research study [0.03%]
免疫治疗晚期癌症试验中生活质量结果和生存率的系统评价和元研究
Annarita Avanzo,Fabio Salomone,Massimo Di Maio et al.
Annarita Avanzo et al.
We examined QoL results in phase III randomized controlled trials (RCTs) investigating immune checkpoint inhibitors (ICIs) in advanced cancers and their correlation with overall survival (OS) and progression-free survival (PFS).
耗时 0.31056 秒，为您在
48685294
条记录里面共找到 10000 篇文章 [XML]